Patients with a normal karyotype are considered intermediate risk advances in molecular genetic research enabled a better understanding of the mechanisms by which molecular events cause blood malignancies. Techniques such as PCR, fluorescence in situ hybridization, and comparative genomic hybridization have improved the ability to recognize these molecular lesions.